ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023

05 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 Sep 2023 17:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Participate at Investor Conferences in September

31 Aug 2023 09:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 Aug 2023 17:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update

03 Aug 2023 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

31 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update

27 Jul 2023 17:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 Jul 2023 17:00:00 By Nasdaq GlobeNewswire

Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy

12 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

06 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts

21 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 Jun 2023 17:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

07 Jun 2023 17:00:00 By Nasdaq GlobeNewswire

Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)

05 Jun 2023 16:00:53 By Nasdaq GlobeNewswire

Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit

19 May 2023 08:30:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 May 2023 17:00:00 By Nasdaq GlobeNewswire

Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.

17 May 2023 08:00:01 By Nasdaq GlobeNewswire

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting

08 May 2023 16:02:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at Bank of America’s 2023 Health Care Conference

05 May 2023 16:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update

04 May 2023 16:01:00 By Nasdaq GlobeNewswire